MI
CRVS icon

Markowski Investments’s Corvus Pharmaceuticals CRVS Stock Holding History

Markowski Investments’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4K Buy
+1,500
New +$20.8K ﹤0.01% 296

Other funds holding CRVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Markowski Investments's CRVS Position: Q2 2026 in Review

Markowski Investments opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 1,500 shares worth $22.4K. The stake represents ﹤0.01% of the portfolio and ranks #296 among its holdings.

111 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Markowski Investments held 1,500 shares of Corvus Pharmaceuticals worth $22.4K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Markowski Investments position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Markowski Investments's portfolio in Q2 2026, its #296 holding.
  • 111 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Markowski Investments's 13F filing for Q2 2026, filed 13 Aug 2026.